What did @dr.karanr actually say?
In a video that's racked up 3.1 million views, Dr. Karan Rajan argued that GLP-1 medications don't "fix" weight loss but instead "change the conditions inside your brain and gut" to make healthy habits easier. He split patients into two camps: those with short-term, situational weight gain who might taper off, and those with chronic obesity as a biological condition who may need these drugs indefinitely. His closing line, that "stopping the GLP-1s doesn't cause the weight regain, it's stopping the habit," is doing a lot of heavy lifting here, and deserves scrutiny.
The framing is mostly responsible. He's not selling miracles. He's not claiming semaglutide cures anything. He's trying to reframe obesity as a chronic disease rather than a character flaw, which is a legitimate clinical position. But some of the nuance gets lost in the 60-second format.
Does the science back this up?
The core claim, that obesity is a chronic biological condition requiring long-term intervention, is well-supported. The evidence on what happens when you stop GLP-1s is also pretty clear, and it complicates his framing slightly.
The STEP 4 trial (Rubino et al., 2021, New England Journal of Medicine) followed patients who stopped semaglutide after 20 weeks. Within a year, two-thirds of the weight lost came back. The SURMOUNT-4 trial (Aronne et al., 2024, JAMA) showed similar regain patterns after stopping tirzepatide. These aren't edge cases. Weight regain after discontinuation is the norm, not the exception.
His point about GLP-1s altering gut-brain signaling is also grounded in real biology. GLP-1 receptors are expressed in the hypothalamus and brainstem, and research from Müller et al. (2022, Nature Reviews Endocrinology) confirms these drugs reduce appetite partly through central nervous system pathways. That part checks out.
What did they get wrong (or right)?
The biggest issue is the claim that "stopping the GLP-1s doesn't cause the weight regain, it's stopping the habit." This is partially true but potentially misleading to a mass audience.
The data from STEP 4 and SURMOUNT-4 shows that weight regain happens even in people who maintain lifestyle changes. The biology of obesity, specifically the reduction in leptin and increase in ghrelin that follows weight loss, doesn't care how many grams of protein you're eating. Tremblay and Chaput (2009, Obesity Reviews) documented this hormonal compensation response years before GLP-1s were mainstream. Blaming regain primarily on "stopping the habit" lets the drug off the hook in a way the clinical data doesn't fully support.
What he got right: the chronic disease framing is accurate and reduces stigma. His comparison to thyroid conditions and blood pressure medications is a fair analogy. And his emphasis on fiber, protein, resistance training, and sleep as non-negotiables is consistent with evidence-based guidelines from the American College of Lifestyle Medicine.
What should you actually know?
If you're considering stopping a GLP-1 medication, the conversation has to happen with a prescribing clinician, not a TikTok comment section. The reasons to stop, cost, side effects, pregnancy, reaching a stable weight, are real. But the expectation that habits alone will hold all the weight loss is not well-supported by clinical data for most people with chronic obesity.
The situational vs. chronic framing he offers is a useful starting point, but it's not a clean binary. Menopause-related weight gain, for instance, often involves the same hormonal dysregulation he associates with chronic obesity, and the research on GLP-1 use in perimenopause is still early. Escalante et al. (2023, Menopause) found significant metabolic overlap between menopause-related and obesity-related weight gain that complicates a simple short-term vs. long-term split.
The honest answer to "do you need GLP-1s forever?" is: many people do, and that's not a failure. For others, a structured taper with close monitoring and realistic expectations is possible. Neither outcome is guaranteed by habits alone.